Table of Contents page: European Journal of Cancer

Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Adoption of multiple primary endpoints in phase III trials of systemic treatments in patients with advanced solid tumours. A systematic review

Clizia Zichi,
Chiara Paratore,
Piera Gargiulo,
...
Teresa Gamba,
Francesco Perrone,
Massimo Di Maio

Published online: April 03, 2021

p49-60

Influence of the competing risk of death on estimates of disease recurrence in trials of adjuvant endocrine therapy for early-stage breast cancer: A secondary analysis of MA.27, MA.17 and MA.17R

Josee-Lyne Ethier,
Geoffrey M. Anderson,
Peter C. Austin,
...
Lily Summers Trasiewicz,
Dongsheng Tu,
Eitan Amir

Published online: April 11, 2021

p117-127

Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis

Francesco Schettini,
Fabiola Giudici,
Ottavia Bernocchi,
...
Aleix Prat,
Giuseppe Curigliano,
Daniele Generali

Published online: April 13, 2021

p134-152

Osimertinib versus osimertinib plus chemotherapy for non–small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial

Kentaro Tanaka,
Hajime Asahina,
Junji Kishimoto,
...
Kenji Sugio,
Satoshi Oizumi,
Isamu Okamoto

Published online: April 01, 2021

p14-22

Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor–positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatment

Mariano Provencio,
Roberto Serna-Blasco,
Fabio Franco,
...
Eloisa Jantus-Lewintre,
Miguel Á. Molina-Vila,
Atocha Romero

Published online: April 05, 2021

p61-72

Open Access

The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non–small-cell lung cancer differ based on PD-L1 expression

Nobuaki Ochi,
Eiki Ichihara,
Nagio Takigawa,
...
Katsuyuki Hotta,
Yoshinobu Maeda,
Katsuyuki Kiura

Published online: April 07, 2021

p73-81

BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapy

Marcel Wiesweg,
Cedric Preuß,
Julia Roeper,
...
Markus Tiemann,
Frank Griesinger,
Martin Schuler

Published online: April 16, 2021

p211-221

Poziotinib treatment in intractable NSCLC: Epidermal growth factor receptor and human epidermal growth factor receptor 2 exon 20 insertion mutation disease

Rafael Rosell,

Andres F. Cardona Zorrilla

Published online: April 03, 2021

p233-234

Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program

Arsela Prelaj,
Achille Bottiglieri,
Claudia Proto,
...
Valter Torri,
Filippo de Braud,
Marina C. Garassino

Published online: April 02, 2021

p235-248

Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy – A multicentre study of 90 patients from the German Dermatooncology Group

Imke Grimmelmann,
Michael Momma,
Lisa Zimmer,
...
Selma Ugurel,
Ralf Gutzmer
for the German Dermatooncology Group (DeCOG)

Published online: March 31, 2021

p1-10

Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response

Florentia Dimitriou,
Anne Zaremba,
Clara Allayous,
...
Phil F. Cheng,
Reinhard Dummer,
Joanna Mangana

Published online: April 03, 2021

p37-48

Open Access

Combining CNN-based histologic whole slide image analysis and patient data to improve skin cancer classification

Julia Höhn,
Eva Krieghoff-Henning,
Tanja B. Jutzi,
...
Gerardo Ferrara,
Sarah Haggenmüller,
Titus J. Brinker

Published online: April 07, 2021

p94-101

Open Access

High discordance rate in assessing sentinel node positivity in cutaneous melanoma: Expert review may reduce unjustified adjuvant treatment

Mary-Ann El Sharouni,
Annelien E. Laeijendecker,
Karijn PM. Suijkerbuijk,
...
Paul J. van Diest,
Carla H. van Gils,
Willeke AM. Blokx

Published online: April 10, 2021

p105-113

Open Access

Novel PD-1 inhibitor prolgolimab: expanding non-resectable/metastatic melanoma therapy choice

Sergey Tjulandin,
Lev Demidov,
Vladimir Moiseyenko,
...
Natalya Fadeyeva,
Mariia Shustova,
Ivan Kuryshev

Published online: April 17, 2021

p222-232

Open Access

Evidence-based recommendations on categories for extent of resection in diffuse glioma

Philipp Karschnia,
Michael A. Vogelbaum,
Martin van den Bent,
...
Mitchel S. Berger,
Michael Weller,
Joerg-Christian Tonn

Published online: April 02, 2021

p23-33

Open Access

Early ctDNA response to chemotherapy. A potential surrogate marker for overall survival

Anders Jakobsen,
Rikke F. Andersen,
Torben F. Hansen,
...
Karina D. Steffensen,
Caroline B. Thomsen,
Sara W.C. Wen

Published online: April 12, 2021

p128-133

Open Access

Functional measurement of mitogen-activated protein kinase pathway activation predicts responsiveness of RAS-mutant cancers to MEK inhibitors

Shumei Kato,
Robert Porter,
Ryosuke Okamura,
...
Gabi Tarcic,
Michael Vidne,
Razelle Kurzrock

Published online: April 14, 2021

p184-192

Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy

E. Ghisoni,
A. Wicky,
H. Bouchaab,
...
M.A. Cuendet,
M. Di Maio,
O. Michielin

Published online: April 14, 2021

p153-164

Open Access

Applications of single-cell and bulk RNA sequencing in onco-immunology

Maria Kuksin,
Daphné Morel,
Marine Aglave,
...
Andrei Zinovyev,
Daniel Gautheret,
Loïc Verlingue

Published online: April 15, 2021

p193-210

Open Access

Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years

Emmanuelle Jacquet,
Ghania Kerouani-Lafaye,
Francoise Grude,
...
Gaëlle Guyader,
Lotfi Boudali,
Nicolas Albin

Published online: April 07, 2021

p82-90

Open Access

Perspectives on natural compounds in chemoprevention and treatment of cancer: an update with new promising compounds

Abedul Haque,
Daniel Brazeau,
Arm R. Amin

Published online: April 14, 2021

p165-183

Cemiplimab removed from reimbursable drugs in France

Félix Pham,
Bénédicte Reynaud,
Bertrand Favier,
Sophie Darnis,
Mona Amini-Adle

Published online: April 01, 2021

p11-13

Association of thrombotic microangiopathy with atezolizumab therapy in cancer patients

Hassan Izzedine,
Alexis Mathian,
Laurence Albiges,
Stéphane Champiat,
Isabelle Brocheriou

Published online: April 02, 2021

p34-36

Abscopal antitumor effect in a patient with melanoma and coronavirus disease 2019

Hugo Herrscher,
Benoit Sauer,
Pierre Truntzer,
Caroline Robert

Published online: March 14, 2021

p91-93

$High levels of TNFα in patients with COVID-19 refractory to tocilizumab$

High levels of TNFα in patients with COVID-19 refractory to tocilizumab

F.X. Danlos,
F. Ackermann,
J. Rohmer,
M. Roumier,
A. Marabelle,
J.M. Michot

Published online: March 20, 2021

p102-104

Pericarditis during chemoimmunotherapy for non–small cell lung cancer: an adverse event to prevent and recognise

Francesca Jacobs,
Simona Carnio,
Paola De Stefanis,
Alessia Luciano,
Silvia Novello

Published online: April 12, 2021

p114-116

May 2021

Clinical trial methodology

Adoption of multiple primary endpoints in phase III trials of systemic treatments in patients with advanced solid tumours. A systematic review

Breast cancer

Influence of the competing risk of death on estimates of disease recurrence in trials of adjuvant endocrine therapy for early-stage breast cancer: A secondary analysis of MA.27, MA.17 and MA.17R

Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis

Lung cancer

Osimertinib versus osimertinib plus chemotherapy for non–small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial

Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor–positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatment

The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non–small-cell lung cancer differ based on PD-L1 expression

BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapy

Poziotinib treatment in intractable NSCLC: Epidermal growth factor receptor and human epidermal growth factor receptor 2 exon 20 insertion mutation disease

Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program

Melanoma and skin cancers

Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy – A multicentre study of 90 patients from the German Dermatooncology Group

Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response

Combining CNN-based histologic whole slide image analysis and patient data to improve skin cancer classification

High discordance rate in assessing sentinel node positivity in cutaneous melanoma: Expert review may reduce unjustified adjuvant treatment

Novel PD-1 inhibitor prolgolimab: expanding non-resectable/metastatic melanoma therapy choice

Neuro-oncology

Evidence-based recommendations on categories for extent of resection in diffuse glioma

Basic science and preclinical research

Early ctDNA response to chemotherapy. A potential surrogate marker for overall survival

Functional measurement of mitogen-activated protein kinase pathway activation predicts responsiveness of RAS-mutant cancers to MEK inhibitors

Tumour Immunology and Immunotherapy

Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy

Applications of single-cell and bulk RNA sequencing in onco-immunology

Other

Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years

Perspectives on natural compounds in chemoprevention and treatment of cancer: an update with new promising compounds

Correspondence

Cemiplimab removed from reimbursable drugs in France

Association of thrombotic microangiopathy with atezolizumab therapy in cancer patients

Abscopal antitumor effect in a patient with melanoma and coronavirus disease 2019

High levels of TNFα in patients with COVID-19 refractory to tocilizumab

Pericarditis during chemoimmunotherapy for non–small cell lung cancer: an adverse event to prevent and recognise